HLX-43

N/A

Report date: 2026/04/25 20:00:23

Base Information

Drug NameHLX-43
Drug Alias NameHLX-43HLX43
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Camptothecin payload
Mechanisms of ActionAnti-Programmed death-ligand 1DNA topoisomerase I inhibitors
TargetsProgrammed death-ligand 1DNA topoisomerase I
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[20] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Henlius Biologics Co LtdShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[20] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A